A5054881858- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Bladder and Urothelial Cancer Treatments
- Statistical Methods in Clinical Trials
- Bone Tumor Diagnosis and Treatments
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
- Musculoskeletal synovial abnormalities and treatments
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Soft tissue tumor case studies
- Urinary and Genital Oncology Studies
- BRCA gene mutations in cancer
- Radiomics and Machine Learning in Medical Imaging
- PARP inhibition in cancer therapy
- Prostate Cancer Treatment and Research
- Esophageal Cancer Research and Treatment
- Ethics in Clinical Research
- Renal and related cancers
McGill University
2015-2025
McGill University Health Centre
2014-2025
Princess Margaret Cancer Centre
2019-2023
University of Toronto
2019-2023
GTx (United States)
2023
Jersey City Medical Center
2022
Policlinico di Modena
2019
Kennedy Memorial Hospital
2016-2017
Jefferson University Hospitals
2016-2017
Rowan University
2016-2017
Abstract Purpose: Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm caused by dysregulation of the colony-stimulating factor 1 (CSF1) gene and overexpression CSF1 ligand. Surgery standard care for most patients, but there are limited treatment options patients with TGCT not amenable to surgery. This study evaluates vimseltinib, an investigational, oral, switch-control tyrosine kinase inhibitor designed selectively potently inhibit receptor. Patients Methods:...
BackgroundTo date, economic analyses of tissue-based next generation sequencing genomic profiling (NGS) for advanced solid tumors have typically required models with assumptions, little real-world evidence on overall survival (OS), clinical trial enrollment or end-of-life quality care.MethodsCost consequence analysis NGS testing (555 161-gene panels) through the OCTANE (NCT02906943). This is a longitudinal, propensity score-matched retrospective cohort study in Ontario, Canada using linked...
471 Background: Papillary renal cell carcinoma (pRCC) is the most common non-clear RCC (nccRCC) representing up to 15% of RCC. First line (1L) phase II trials have evaluated immunotherapy (IO) in combination with IO or tyrosine kinase inhibitors (TKI) nccRCC, but these cohorts are heterogeneous, few comparative results. Therefore, specific value therapy for pRCC remains unquantified. Methods: We conducted an analysis based on prospectively collected data from Canadian Kidney Cancer...
TPS282 Background: Actinium-225 (Ac-225)-based, prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) represents a promising treatment modality for prostate cancer. First-generation PSMA-targeting ligands (e.g., PSMA-617 and PSMA-I&T) paired with Ac-225 have been associated myelosuppression, renal toxicity, xerostomia (1). LY4181530 (previously PNT2001) pairs PSMA-62, next-generation ligand, which was specifically designed to overcome these limitations. It employs...
51 Background: The treatment landscape of mPC is rapidly evolving to include more precision therapies for patients with actionable genomic alterations. Specifically, deleterious aberrations in HRR genes (HRRm) confer sensitivity PARP inhibitors (PARPi) which have demonstrated survival benefit this context. Therefore, accurate identification potentially HRRm indicated. Somatic testing archival tissue inadequate due poor DNA quality or lack availability 30-40% cases. We evaluated whether...
CAR T therapy for solid tumors is limited by a lack of safe and uniformly expressed cell-surface targets. Here, we identify the MiT fusion-driven protein GPNMB as being highly, homogeneously, stably in primary relapsed translocation-positive alveolar soft part sarcoma (ASPS) renal cell carcinoma (tRCC). We developed GPNMB-targeting called GCAR1 that shows activity against patient-matched cells, organoids xenograft models. First-in-human treatment patient with metastatic ASPS was well...
Clinical practice guidelines (CPGs) are crucial to the of evidence-based medicine. Declared author financial conflicts interest (FCOIs) common in CPGs and have been associated with endorsement treatment. Less is known about undeclared FCOIs.The American Society Oncology (ASCO) website was searched identify all for systemic therapy published between August 2013 June 2018. Data on self-reported FCOIs funding sources were extracted. The Open Payments database then compensation CPG authors....
Approval of drugs is based on randomized trials observing statistically significant superiority an experimental agent over a standard. Statistical significance results from combination effect size and sampling, with larger more likely to translate population effectiveness. We assess sample justification in supporting cancer drug approvals. identified US FDA anti-cancer approvals for solid tumors 2015 2019. extracted data study characteristics, statistical plan, accrual, outcomes. Observed...
Immunotherapy-based systemic treatment (ST) is the standard of care for most patients diagnosed with metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy (CN) has historically shown benefit select mRCC, but its role and timing are not well understood in era immunotherapy. The primary objective this study to assess outcomes who received ST only, CN followed by (CN-ST), (ST-CN). Canadian Kidney Cancer information system (CKCis) database was queried identify de novo mRCC...
LESS IS MORE Off-label Use of Quetiapine in Medical Inpatients and PostdischargeOff-label use antipsychotic medication is increasing, particularly the quetiapine for sleep, owing to its sedating properties. 1 This a cause concern given important adverse effects, including drug-induced diabetes parkinsonism, weight gain, neuroleptic malignant syndrome, oversedation, risk arrhythmia. 2 We describe prospective cohort medical inpatients proportion inhospital that perpetuated on discharge.Methods...
A 56-year-old woman with a new diagnosis of metastatic pancreatic cancer presents to the emergency room generalised fatigue. The patient is afebrile, however, hypotensive and tachycardic. Physical examination shows diffuse lymphadenopathy. Initial laboratory tests indicate that has hyperkalaemia, hypocalcaemia, high lactate dehydrogenase uric acid. was also in renal failure. On basis clinical presentation, diagnosed spontaneous tumour lysis syndrome, despite syndrome never having been...
Background: Transthoracic echocardiography (TTE) is commonly used to assess cardiac morphology and function in cancer patients. The nature, distribution, prevalence of significant echocardiographic abnormalities are unknown. We hypothesized that TTEs performed for or treatment indications, have a high (SA), including large proportion findings may be overlooked by other imaging modalities. Methods: All TTE studies tertiary center over six‐month period, from January June 2007, were reviewed....